PMID- 23246359
OWN - NLM
STAT- MEDLINE
DCOM- 20131029
LR  - 20231213
IS  - 1873-5967 (Electronic)
IS  - 1386-6532 (Linking)
VI  - 56
IP  - 4
DP  - 2013 Apr
TI  - Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 
      patients with unfavorable IL-28B genotype.
PG  - 293-8
LID - S1386-6532(12)00435-0 [pii]
LID - 10.1016/j.jcv.2012.11.015 [doi]
AB  - BACKGROUND: Viral kinetics and host interleukin 28B (IL-28B) genotype determine 
      treatment outcome in hepatitis C virus genotype 1 (HCV-1) infection. OBJECTIVES: 
      We aimed to explore the interplay between interferon responsiveness at treatment 
      week 4 and IL28B genotype in the achievement of a sustained virological response 
      (SVR; undetectable HCV RNA 24-weeks after end-of-treatment). STUDY DESIGNS: 
      Rs8099917 genotypes were determined in 528 HCV-1 patients with 
      peginterferon/ribavirin. Interferon responsiveness were evaluated by the degree 
      of week 4 viral reduction: <1 log(10) IU/mL, 1-2 logs(10) IU/mL, 2-3 logs(10) 
      IU/mL, 3-4 logs(10) IU/mL and >/=4 logs(10) IU/mL reduction and/or undetectable HCV 
      RNA, respectively. RESULTS: The SVR rate was significantly higher in patients 
      with great interferon responsiveness at week 4. A great interferon responsiveness 
      was associated with younger age (P < 0.0001), lower body mass index (P = 0.0056), 
      lower aspartate aminotransferase levels (P = 0.0009), higher hemogloblin 
      concentration (P = 0.0033), higher platelet counts (P < 0.0001), male gender (P < 
      0.0001) and rs809997 TT-genotype (P < 0.0001). Comparing to non-TT genotype 
      patients, TT genotype patients had a significantly higher SVR rate with moderate 
      viral reduction (1-3 logs(10) IU/mL) at week 4 (58.9% vs. 18.2%, P < 0.001), and 
      the SVR rate did not differ between TT/non-TT patients on the extreme ends (<1 or 
      >3 log(10) IU/mL reduction) of week 4 interferon responsiveness. For non-TT 
      genotype carriers who were with <3 logs(10) reduction, none (0/15) could have a 
      complete early virological response and only 10.9% (7/64) of the patients had an 
      SVR. CONCLUSIONS: More profound interferon responsiveness is mandatory for HCV-1 
      patients with unfavorable IL-28B genotype.
CI  - Copyright (c) 2012 Elsevier B.V. All rights reserved.
FAU - Huang, Chung-Feng
AU  - Huang CF
AD  - Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical 
      University, Kaohsiung, Taiwan.
FAU - Yu, Ming-Lung
AU  - Yu ML
FAU - Kao, Jia-Horng
AU  - Kao JH
FAU - Tseng, Tai-Chung
AU  - Tseng TC
FAU - Yeh, Ming-Lun
AU  - Yeh ML
FAU - Huang, Jee-Fu
AU  - Huang JF
FAU - Dai, Chia-Yen
AU  - Dai CY
FAU - Lin, Zu-Yau
AU  - Lin ZY
FAU - Chen, Shinn-Cherng
AU  - Chen SC
FAU - Wang, Liang-Yen
AU  - Wang LY
FAU - Juo, Suh-Hang Hank
AU  - Juo SH
FAU - Chuang, Wan-Long
AU  - Chuang WL
FAU - Liu, Chen-Hua
AU  - Liu CH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Clin Virol
JT  - Journal of clinical virology : the official publication of the Pan American 
      Society for Clinical Virology
JID - 9815671
RN  - 0 (Antiviral Agents)
RN  - 0 (Hemoglobins)
RN  - 0 (interferon-lambda, human)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Interleukins)
RN  - 0 (RNA, Viral)
RN  - 0 (Recombinant Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - 9008-11-1 (Interferons)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - G8RGG88B68 (peginterferon alfa-2b)
RN  - Q46947FE7K (peginterferon alfa-2a)
SB  - IM
CIN - J Clin Virol. 2013 Aug;57(4):381. PMID: 23688864
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Antiviral Agents/administration & dosage/*pharmacology
MH  - Aspartate Aminotransferases/analysis
MH  - Body Mass Index
MH  - Drug Therapy, Combination
MH  - Female
MH  - Genetic Testing
MH  - Genotype
MH  - Hemoglobins/analysis
MH  - Hepacivirus/*genetics/pathogenicity
MH  - Hepatitis C, Chronic/*drug therapy/virology
MH  - Heterozygote
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/administration & dosage/*pharmacology
MH  - Interferons
MH  - Interleukins/*genetics
MH  - Male
MH  - Middle Aged
MH  - Platelet Count
MH  - Polyethylene Glycols/administration & dosage/*pharmacology
MH  - RNA, Viral/genetics/metabolism
MH  - Recombinant Proteins/administration & dosage/pharmacology
MH  - Ribavirin/administration & dosage/pharmacology
MH  - Sex Factors
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2012/12/19 06:00
MHDA- 2013/10/30 06:00
CRDT- 2012/12/19 06:00
PHST- 2012/08/17 00:00 [received]
PHST- 2012/10/14 00:00 [revised]
PHST- 2012/11/19 00:00 [accepted]
PHST- 2012/12/19 06:00 [entrez]
PHST- 2012/12/19 06:00 [pubmed]
PHST- 2013/10/30 06:00 [medline]
AID - S1386-6532(12)00435-0 [pii]
AID - 10.1016/j.jcv.2012.11.015 [doi]
PST - ppublish
SO  - J Clin Virol. 2013 Apr;56(4):293-8. doi: 10.1016/j.jcv.2012.11.015.